How Will Ocera Therapeutics, Inc. (NASDAQ:OCRX)’s Share Price Respond to Announcement of News That Late-Breaker Abstract Accepted for Presentation

Clinical-stage biopharmaceutical company, Ocera Therapeutics, Inc. (NASDAQ:OCRX), announced that it will release clinical trial data at the Liver Meeting 2016, November 11-15, 2016, in Boston.

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) — Ocera Therapeutics, Inc. (OCRX), today announced that clinical data from STOP-ALF, a Phase 2a clinical trial to evaluate the Safety and Tolerability of Ornithine Phenylacetate (OCR-002) in patients with Acute Liver Failure, will be presented in the late-breaking poster session at The Liver Meeting® 2016, the 67th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held on November 11-15, 2016, in Boston, Massachusetts.

Key findings of this safety study reflected in the abstract include the following:

    No drug-related serious adverse events observed; all doses well-tolerated

    Therapeutic serum levels of phenylacetate (PAA) were achieved at infusion rates of OCR-002 20g/24h

    Therapeutic PAA levels appeared to result in considerable ammonia excretion in urine as phenylacetylglutamine (PAGN), the end product by which PAA clears the neurotoxin ammonia, even in patients with non-oliguric renal failure

“Hyperammonemia can lead to cerebral edema, and remains a significant cause of morbidity and mortality in patients with acute liver failure,” commented William M. Lee, M.D., principal investigator of the study. “We are very excited by the results of this safety trial and hope further studies can be conducted to examine the potential for OCR-002 to help clear the high ammonia levels, and improve the outcome of these patients.”

“We are very pleased this important study has been completed,” said Stan Bukofzer, M.D., Chief Medical Officer of Ocera. “In light of the safety profile and tolerability of OCR-002 in this very ill patient population, we believe it could have potential in the management of Acute Liver Failure.”

Additional details including the presentation abstract can be found on the AASLD website by clicking this link.

About STOP-ALF

The Phase 2a study was a multi-center, open-label study, conducted in two cohorts of patients diagnosed with acute liver failure. Patients were treated pursuant to one of four escalating dosing regimens of intravenously-administered OCR-002, an ammonia scavenger, which were advanced only after safety and certain pharmacokinetic data were reviewed. Cohort 1 was comprised of affected patients with minimal renal dysfunction (defined as serum creatinine ≤ 1.5 mg/dL and mean arterial pressure of > 65 mm Hg). Cohort 2 included affected patients with compromised renal function (defined as serum creatinine > 1.5 mg/dL and < 10 mg/dL with mean arterial pressure of > 65 mm Hg). Dose levels within the four regimens ranged from approximately 3.33 g/24h to 20 g/24h for up to 5 treatment days. 36 of 47 patients enrolled are considered evaluable having completed at least 72 hours of treatment. The study, ClinicalTrials.gov: NCT00518440, was conducted by the Acute Liver Failure Study Group, grant number U-01-58369, an NIH-sponsored network of university tertiary care liver transplant sites, with support and supply of study medication from Ocera.

About Acute Liver Failure (ALF)

Acute liver failure is a rare syndrome with a significant mortality rate affecting an estimated 2,000 previously healthy individuals annually in the U.S. ALF is a rapid deterioration of liver function, often due to acetaminophen and idiosyncratic drug reactions, resulting in the liver’s inability to clear the circulating toxin Ammonia, which can lead to cerebral edema, intracranial hypertension, brainstem herniation and death.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and acute-on-chronic liver disease.

Ocera’s HE clinical development efforts include an ongoing Phase 2b clinical trial, STOP-HE, which is evaluating the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. The Company expects to complete enrollment in the STOP-HE trial in the fourth quarter of 2016 with top-line data to be published soon thereafter.

Concurrent with STOP-HE, Ocera is evaluating orally-available OCR-002 in a Phase 1 study in patients with cirrhosis as a chronic use option to maintain remission of HE. Results of part one of this study are expected to be published by the end of 2016 with part two expected to commence in the first half of 2017. For additional information, please see www.ocerainc.com.

Original Source

ocera-therapeutics-graph

Ocera Therapeutics, Inc. (NASDAQ:OCRX) shares have moved -3.85% on the news thus far today and have traded in the range of $2.30 – 2.60 during the current session. In order to take a look at where the stock might be headed longer term, investors often look to research firms that cover the stock. Sell-side research firms currently have a consensus one-year price target of $9.75 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  The sell-side analysts are projecting earnings per share of $-0.34 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-1.36 per share according to First Call.

Are Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) Ready to Explode?  Sign up to our Newsletter to be the First to Know 

Sign up to get our Free Penny Stock Picks Before the Street!

In looking at where the stock is trading on a technical level, the stock is trading -2.85% away from its 50-day moving average of $2.57.  Based on the most recent available data, the equity is -45.30% off of its 52-week high of $4.57 and +42.05% away from its 52-week low which is $1.76.

Today, the stock opened at $2.60 and the last bid at the time of writing stood at $2.50.  During the session thus far, the equity dipped down to $2.30 and touched $2.60 as the high point.  Ocera Therapeutics, Inc. (NASDAQ:OCRX) has a market cap of $54.63M and has seen an average daily volume of 216,063 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Related posts

Leave a Comment